• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Noveome Biotherapeutics raises $15 million for development of ST266

Noveome Biotherapeutics said that it has closed a $15 million Series D financing round that will help to fund further development of its ST266 biologic. Intranasal formulations of ST266 are in development for the treatment of optic nerve disease and for chronic traumatic encephalopathy (CTE). In 2017, Noveome announced positive data from a preclinical study of … [Read more...] about Noveome Biotherapeutics raises $15 million for development of ST266

Otitopic announces plans to develop its inhaled aspirin for the treatment of lung cancer

Otitopic, which recently announced that it received a new patent for the us of inhaled aspirin for the treatment of myocardial infarction, now says that it also plans to develop its Asprihale aspirin DPI for the treatment of lung cancer. The company cites published studies showing lower risk of lung cancer with aspirin use and the potential of aspirin to inhibit … [Read more...] about Otitopic announces plans to develop its inhaled aspirin for the treatment of lung cancer

Pulmatrix raises $16.6 million in public offering

Pulmatrix said that it has closed a public offering with expected gross proceeds of $16.6 million that will be used primarily for development of its inhaled therapies, especially Pulmazole inhaled itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. The company had previously said that it expected to raise $14.4 … [Read more...] about Pulmatrix raises $16.6 million in public offering

Par Pharmaceutical launches authorized generic of Proventil HFA in US

Endo International has announced that its subsidiary Endo Procurement Operations Limited recently reached an agreement with Merck to distribute an authorized generic of Proventil HFA albuterol sulfate MDI in the US. Endo operating company Par Pharmaceutical has already started shipping the inhaler, the company said. 3M Drug Delivery Systems manufactures Proventil … [Read more...] about Par Pharmaceutical launches authorized generic of Proventil HFA in US

Opiant Pharmaceuticals gets additional funding for intranasal nalmefene

Opiant Pharmaceuticals has received an additional $3 million from a 3-year grant awarded in 2018 by the National Institutes of Health’s (“NIH”) National Institute on Drug Abuse (“NIDA”) to support development of OPNT003 intranasal nalmefene for the treatment of opioid overdose. The company previously received $2.6 million from the grant, which is worth up to a total … [Read more...] about Opiant Pharmaceuticals gets additional funding for intranasal nalmefene

Cip Tec and Pulmatrix agree on terms for acquisition of rights to Pulmazole itraconazole DPI for ABPA

Pulmatrix announced that it has signed an agreement with Cipla subsidiary Cipla Technologies (Cip Tec) that "lays the groundwork" for Cip Tec to acquire the rights to Pulmazole (PUR1900) inhaled dry powder itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. A definitive deal is expected in the 2nd quarter of 2019, … [Read more...] about Cip Tec and Pulmatrix agree on terms for acquisition of rights to Pulmazole itraconazole DPI for ABPA

MannKind gets first milestone payment from United Therapeutics for treprostinil DPI development

MannKind Corporation has announced that it has received a $12.5 million milestone payment from United Therapeutics for the first milestone related to development of a treprostinil Technosphere (TreT) DPI for the treatment of pulmonary arterial hypertension. The company did not specify what milestone had been achieved. United Therapeutics and MannKind announced the … [Read more...] about MannKind gets first milestone payment from United Therapeutics for treprostinil DPI development

Third Pole Therapeutics to collaborate with Actelion on inhaled nitric oxide development

Third Pole Therapeutics, which is developing an inhaled nitric oxide (iNO) generator, has announced a strategic collaboration agreement with Actelion Pharmaceuticals. Details of the agreement were not specified. Third Pole's iNO platform is designed for more convenient delivery than the compressed gas cylinders currently in use. The Third Pole device is primarily … [Read more...] about Third Pole Therapeutics to collaborate with Actelion on inhaled nitric oxide development

Janssen partners with Monash University on development of inhaled oxytocin

Johnson & Johnson subsidiary Janssen Pharmaceutica has announced that it signed a sponsored research agreement with Monash University's Monash Institute of Pharmaceutical Sciences (MIPS) for development of an inhaled dry powder oxytocin for the prevention and treatment of postpartum hemorrhage. No financial details were included in the announcement. According … [Read more...] about Janssen partners with Monash University on development of inhaled oxytocin

Ultibro Breezhaler and Seebri Breezhaler launched in China

According to Sosei, Novartis has launched the Ultibro Breezhaler indacaterol/glycopyrronium DPI and the Seebri Breezhaler glycopyrronium DPI in China for the treatment of COPD. Huizheng Technology acquired the Chinese licenses for the inhalers from Novartis and has filed applications to add both DPIs to the national health insurance drug list, Sosei … [Read more...] about Ultibro Breezhaler and Seebri Breezhaler launched in China

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 59
  • Page 60
  • Page 61
  • Page 62
  • Page 63
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews